Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project

Microorganisms

卷:9

the PSERENADE Team¹  Michael G. Bruce²  Kevin J. Scott³  Néhémie Nzoyikorera⁴  Jesús Castilla⁵  Pilar Ciruela⁵  Heather Cook⁶  Larisa Savrasova⁷  Godfrey Bigogo⁸  Metka Paragi⁹  Jackie Kleynhans¹⁰  Anne von Gottberg¹⁰  Samir K. Saha¹¹  Nadja Sinkovec Zorko¹²  Karl Gústaf Kristinsson¹³  Tiia Lepp¹⁴  J. Pekka Nuorti¹⁵  Didrik F. Vestrheim¹⁶  Romina Camilli¹⁷  Lena Petrova Setchanova¹⁸  Pak-Leung Ho¹⁹  Stefanie Desmet²⁰  James D. Kellner²¹  Inci Yildirim²²  Philippe De Wals²³  Krow Ampofo²⁴  Sara de Miguel²⁵  Camelia Savulescu²⁶  Yvonne Galloway²⁷  J. Anthony Scott²⁸  Eunice W. Kagucia²⁸  Sabrina Bacci²⁹  Grant A. Mackenzie³⁰  Shamez N. Ladhani³¹  Daniel R. Feikin³²  Palle Valentiner-Branth³³  Grettel Chanto Chacón³⁴  Rodrigo Puentes³⁵  Mary Corcoran³⁶  Marissa K. Hetrich³⁷  Meagan E. Peterson³⁷  Maria Deloria Knoll³⁷  Julia C. Bennett³⁷  Yangyupei Yang³⁷  Laura L. Hammitt³⁷  Maria Garcia Quesada³⁷  Kyla Hayford³⁷  Jenna N. Sinkevitch³⁷  Maria Eugenia León³⁸  Todd D. Swarthout³⁹  Eric Rafai⁴⁰  Tamara Pilishvili⁴¹  Tuya Mungun⁴²  Sanjay Jayasinghe⁴³  Mirjam J. Knol⁴⁴  Jana Kozakova⁴⁵  Maria-Cristina C. Brandileone⁴⁶  Theano Georgakopoulou⁴⁷  Mark van der Linden⁴⁸  Anna Skoczyńska⁴⁹  Lucia Mad’arová⁵⁰  Lucia Helena De Oliveira⁵¹  Kostas Danis⁵²  Claudia S. Lara⁵³  Guanhao Chan⁵⁴  Markus Hilty⁵⁵  Ron Dagan⁵⁶  Allison McGeer⁵⁷  Kazunori Oishi⁵⁸  Laurie Aukes⁵⁹  Jason M. Mwenda⁶⁰  Adam L. Cohen⁶¹  Fatima Serhan⁶¹ 

[1] ;

[2] Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, AK 99508, USA;

[3] Bacterial Respiratory Infection Service, Scottish Microbiology Reference Laboratory, NHS GG&C, Glasgow, G31 2ER, UK;

[4] Bacteriology-Virology and Hospital Hygiene Laboratory, Ibn Rochd University Hospital Centre, Casablanca 20250, Morocco;

[5] CIBER Epidemiología y Salud Pública, (CIBERESP), 28029 Madrid, Spain;

[6] Centre for Disease Control, Department of Health and Community Services, Darwin City, NT 8000, Australia;

[7] Centre for Disease Prevention and Control of Latvia, 1005 Riga, Latvia;

[8] Centre for Global Health Research, Kenya Medical Research Institute, P.O. Box 1578-40100, Kisumu, Kenya;

[9] Centre for Medical Microbiology, National Laboratory of Health, Environment and Food, 2000 Maribor, Slovenia;

[10] Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham, Johannesburg 2192, South Africa;

[11] Child Health Research Foundation, Dhaka 1207, Bangladesh;

[12] Communicable Diseases Centre, National Institute of Public Health, 1000 Ljubljana, Slovenia;

[13] Department of Clinical Microbiology, Landspitali-The National University Hospital, Hringbraut, 101 Reykjavik, Iceland;

[14] Department of Communicable Disease and Control and Health Protection, Public Health Agency of Sweden, 171 82 Solna, Sweden;

[15] Department of Health Security, Finnish Institute for Health and Welfare, 00271 Helsinki, Finland;

[16] Department of Infection Control and Vaccine, Norwegian Institute of Public Health, 0456 Oslo, Norway;

[17] Department of Infectious Diseases, Italian National Institute of Health (Istituto Superiore di Sanità, ISS), 00161 Rome, Italy;

[18] Department of Medical Microbiology, Medical University of Sofia, Faculty of Medicine, 1431 Sofia, Bulgaria;

[19] Department of Microbiology and Carol Yu Centre for Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China;

[20] Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium;

[21] Department of Pediatrics, University of Calgary, and Alberta Health Services, Calgary, AB T3B 6A8, Canada;

[22] Department of Pediatrics, Yale New Haven Children’s Hospital, New Haven, CT 06504, USA;

[23] Department of Social and Preventive Medicine, Laval University, Québec, QC G1V 0A6, Canada;

[24] Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA;

[25] Epidemiology Department, Dirección General de Salud Pública, 28009 Madrid, Spain;

[26] Epidemiology Department, Epiconcept, 75012 Paris, France;

[27] Epidemiology Team, Institute of Environmental Science and Research, Porirua, Wellington 5022, New Zealand;

[28] Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine-Coast, P.O. Box 230-80108, Kilifi, Kenya;

[29] European Centre for Disease Prevention and Control, 169 73 Solna, Sweden;

[30] Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, Keppel St, London WC1E 7HT, UK;

[31] Immunisation and Countermeasures Division, Public Health England, London NW9 5EQ, UK;

[32] Independent Consultant, 1296 Coppet, Switzerland;

[33] Infectious Disease Epidemiology and Prevention, Statens Serum Institut, DK-2300 Copenhagen, Denmark;

[34] Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud, Tres Ríos, 30301 Cartago, Costa Rica;

[35] Instituto de Salud Pública de Chile, Santiago 7780050, Santiago Metropolitan, Chile;

[36] Irish Meningitis and Sepsis Reference Laboratory, Children’s Health Ireland at Temple Street, Temple Street, D01 YC76 Dublin 1, Ireland;

[37] Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA;

[38] Laboratorio Central de Salud Pública, Asunción, Paraguay (Central Laboratory of Public Health, Asunción, Paraguay), Asunción, Paraguay;

[39] Malawi-Liverpool-Wellcome Trust Clinical Research Programme, P.O. Box 30096, Chichiri, Blantyre, Malawi;

[40] Ministry of Health and Medical Services, Suva, Fiji;

[41] National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA;

[42] National Center of Communicable Diseases (NCCD), Ministry of Health, Bayanzurkh District, Ulaanbaatar 13336, Mongolia;

[43] National Centre for Immunisation Research and Surveillance and Discipline of Child and Adolescent Health, Children’s Hospital Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia;

[44] National Institute for Public Health and the Environment, 3721 MA Bilthoven, The Netherlands;

[45] National Institute of Public Health (NIPH), 100 42 Praha, Czech Republic;

[46] National Laboratory for Meningitis and Pneumococcal Infections, Center of Bacteriology, Institute Adolfo Lutz (IAL), São Paulo 01246-902, Brazil;

[47] National Public Health Organisation, 15123 Athens, Greece;

[48] National Reference Center for Streptococci, Department of Medical Microbiology, University Hospital RWTH Aachen, 52074 Aachen, Germany;

[49] National Reference Centre for Bacterial Meningitis, National Medicines Institute, 00-725 Warsaw, Poland;

[50] National Reference Centre for Pneumococcal and Haemophilus Diseases, Regional Authority of Public Health, 975 56 Banská Bystrica, Slovakia;

[51] Pan American Health Organization, World Health Organization, Washington, DC 20037, USA;

[52] Santé Publique France, the French National Public Health Agency, FR-94410 Saint Maurice, France;

[53] Servicio de Bacteriología Clínica, Departamento de Bacteriología, INEI-ANLIS “Dr. Carlos G. Malbrán”, Buenos Aires C1282 AFF, Argentina;

[54] Singapore Ministry of Health, Communicable Diseases Division, Singapore 308442, Singapore;

[55] Swiss National Reference Centre for invasive Pneumococci, Institute for Infectious Diseases, University of Bern, 3012 Bern, Switzerland;

[56] The Faculty of Health Sciences, Ben-Gurion University of the Negev, 8410501 Beer-Sheva, Israel;

[57] Toronto Invasive Bacterial Diseases Network, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada;

[58] Toyama Institute of Health, Imizu, Toyama 939-0363, Japan;

[59] Vaccine Study Center, Kaiser Permanente, Oakland, CA 94612, USA;

[60] World Health Organization Regional Office for Africa, P.O. Box 06, Brazzaville, Congo;

[61] World Health Organization, 1202 Geneva, Switzerland;

关键词: global;    invasive pneumococcal disease;    pneumococcal meningitis;    surveillance;    pneumococcal conjugate vaccines;   

DOI  :  10.3390/microorganisms9040742

来源: DOAJ

【 摘 要 】

Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project aimed to evaluate the global evidence to estimate the impact of PCV10/13 by age, product, schedule, and syndrome. Here we systematically characterize and summarize the global landscape of routine serotype-specific IPD surveillance in PCV10/13-using countries and describe the subset that are included in PSERENADE. Of 138 countries using PCV10/13 as of 2018, we identified 109 with IPD surveillance systems, 76 of which met PSERENADE data collection eligibility criteria. PSERENADE received data from most (n = 63, 82.9%), yielding 240,639 post-PCV10/13 introduction IPD cases. Pediatric and adult surveillance was represented from all geographic regions but was limited from lower income and high-burden countries. In PSERENADE, 18 sites evaluated PCV10, 42 PCV13, and 17 both; 17 sites used a 3 + 0 schedule, 38 used 2 + 1, 13 used 3 + 1, and 9 used mixed schedules. With such a sizeable and generally representative dataset, PSERENADE will be able to conduct robust analyses to estimate PCV impact and inform policy at national and global levels regarding adult immunization, schedule, and product choice, including for higher valency PCVs on the horizon.

【 授权许可】

Unknown